GSK Says CDC Panel Recommends Penmenvy for Adolescent Meningococcal Vaccination

Dow Jones2025-04-17

By Stephen Nakrosis

GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.

Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added.

In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years.

Vaccine doses will be ready for use in the U.S. in summer, GSK said.

Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

(END) Dow Jones Newswires

April 16, 2025 17:41 ET (21:41 GMT)

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2528209335?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-17 05:41","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2528209335","market":"fut","top_or_hot":-1,"title":"GSK Says CDC Panel Recommends Penmenvy for Adolescent Meningococcal Vaccination","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule. \n</p>\n<p>\n  Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added. \n</p>\n<p>\n  In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years. \n</p>\n<p>\n  Vaccine doses will be ready for use in the U.S. in summer, GSK said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GSK Says CDC Panel Recommends Penmenvy for Adolescent Meningococcal Vaccination</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGSK Says CDC Panel Recommends Penmenvy for Adolescent Meningococcal Vaccination\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-17 05:41</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Stephen Nakrosis \n</p>\n<pre>\n \n</pre>\n<p>\n  GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule. \n</p>\n<p>\n  Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added. \n</p>\n<p>\n  In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years. \n</p>\n<p>\n  Vaccine doses will be ready for use in the U.S. in summer, GSK said. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 16, 2025 17:41 ET (21:41 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1829250122.USD","symbol_name":"高盛欧洲核心股票组合Acc","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2528209335","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2528209335","pubTimestamp":1744839660,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule.Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added.In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years.Vaccine doses will be ready for use in the U.S. in summer, GSK said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1829250122.USD":"高盛欧洲核心股票组合Acc","BK4585":"ETF&股票定投概念","GSK.UK":"葛兰素史克","BK4532":"文艺复兴科技持仓","GSK":"葛兰素史克","BK4588":"碎股","CDC":"VictoryShares US EQ Income Enhanced Volatility Wtd ETF","BK4007":"制药"},"translate_title":"葛兰素史克表示CDC小组建议Penmenvy用于青少年脑膜炎球菌疫苗接种","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"GSK.UK":0.6,"CDC":1,"GSK":1},"content_text":"By Stephen Nakrosis \n\n\n \n\n\n  GSK said a Centers for Disease Control and Prevention advisory board called for its drug Penmenvy to be part of the adolescent meningococcal vaccination schedule. \n\n\n  Penmenvy was recommended to help protect people who are more than 10 years old against disease-causing serogroups of Neisseria meningitidis, as an alternative to the administration of several separate vaccinations, GSK said Wednesday. The recommendation will be reviewed and if adopted would allow for vaccination in fewer doses, which may simplify delivery and improve immunization rates, GSK added. \n\n\n  In February, the Food and Drug Administration approved the company's MenABCWY vaccine for use in individuals aged 10 through 25 years. \n\n\n  Vaccine doses will be ready for use in the U.S. in summer, GSK said. \n\n\n \n\n\n  Write to Stephen Nakrosis at stephen.nakrosis@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 16, 2025 17:41 ET (21:41 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2528209335","isCrawlerRequest":true}